EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study

Fabio Salvatore Macaluso, Elvira D'Antonio, Walter Fries, Anna Viola, Omar Ksissa, Maria Cappello, Stefano Muscarella, Nunzio Belluardo, Emiliano Giangreco, Filippo Mocciaro, Roberto Di Mitri, Concetta Ferracane und 8 weitere

Digestive and Liver Disease · 2024-01 · 56 (1) · 15-20

DOI: 10.1016/j.dld.2023.08.061 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Digestive and Liver Disease, 2024-01. Verfasst von Fabio Salvatore Macaluso und 19 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory bowel disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy. Electronic address: fsmacaluso@gmail.com. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Real-world evidence is needed to determine the value of tofacitinib (TOFA) for the treatment of ulcerative colitis (UC). AIM: To assess the safety and effectiveness of TOFA in clinical practice. METHODS: TOFA-UC is a multicenter, observational study performed among the Sicilian Network for Inflammatory Bowel Disease (SN-IBD). All consecutive patients with UC starting TOFA from its introduction in Sicily (July 2021) to July 2022 were included. RESULTS: 111 patients were included (mean follow-up: 31.7 ± 14.9 weeks; biologic-experienced: 92.8%). Nineteen adverse events were reported (17.1%; incidence rate: 28.2 per 100 patient years), including 11 cases of hypercholesterolemia and 3 infections (no cases of herpes zoster reactivation. At week 8, the rates of clinical response, steroid free clinical remission, and CRP normalization were 74.8%, 45.0%, and 56.9%, respectively, and 68.5%, 51.4%, and 65.2%, respectively, at the end of follow-up. Eighteen patients experienced a loss of response after successful induction (21.7%; incidence rate: 33.2 per 100 patient years). Twenty-six patients (23.4%) discontinued TOFA over time, of whom 3 due to AEs, and 23 to non response or loss of response. CONCLUSIONS: TOFA is safe and effective in patients with UC, including those with history of multiple failures to biological therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeInflammatory Bowel DiseasesHumansPiperidinesPyrimidinesFurans

Stichwörter der Autor:innen

JAK-inhibitorsReal-worldSN-IBDSafetyTofacitinib

Substanzen

PiperidinestofacitinibPyrimidines5-(tetradecyloxy)-2-furancarboxylic acidFurans

Autor:innen und Institutionen

  • Inflammatory bowel disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy. Electronic address: fsmacaluso@gmail.com.
  • Inflammatory bowel disease Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy; Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, Salerno, Italy.
  • Inflammatory bowel disease Unit, "G. Martino" Hospital, Messina, Italy.
  • Gastroenterology & Hepatology Section, PROMISE, University of Palermo, Italy.
  • Gastroenterology Unit, "Guzzardi" Hospital, Vittoria, Italy.
  • Gastroenterology and Endoscopy Unit, "ARNAS Civico - Di Cristina - Benfratelli" Hospital, Palermo, Italy.

Förderung

  • Pfizer

Zitieren

APA

Macaluso, F. S., D'Antonio, E., Fries, W., Viola, A., Ksissa, O., Cappello, M., Muscarella, S., Belluardo, N., Giangreco, E., Mocciaro, F., Di Mitri, R., Ferracane, C., Vitello, A., Grova, M., Renna, S., Casà, A., De Vivo, S., Ventimiglia, M., Orlando, A., & Sicilian Network for Inflammatory Bowel Disease (SN-IBD) (2024). Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study. Digestive and Liver Disease, 56(1), 15-20. https://doi.org/10.1016/j.dld.2023.08.061

Vancouver

Macaluso FS, D'Antonio E, Fries W, Viola A, Ksissa O, Cappello M, et al. Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study. Digestive and Liver Disease. 2024;56(1):15-20. doi:10.1016/j.dld.2023.08.061

BibTeX
@article{Macaluso2024,
  author = {Macaluso, Fabio Salvatore and D'Antonio, Elvira and Fries, Walter and Viola, Anna and Ksissa, Omar and Cappello, Maria and Muscarella, Stefano and Belluardo, Nunzio and Giangreco, Emiliano and Mocciaro, Filippo and Di Mitri, Roberto and Ferracane, Concetta and Vitello, Alessandro and Grova, Mauro and Renna, Sara and Casà, Angelo and De Vivo, Simona and Ventimiglia, Marco and Orlando, Ambrogio and Sicilian Network for Inflammatory Bowel Disease (SN-IBD), Sicilian Network for Inflammatory Bowel Disease (SN-IBD)},
  title = {Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study},
  journal = {Digestive and Liver Disease},
  year = {2024},
  volume = {56},
  number = {1},
  pages = {15--20},
  doi = {10.1016/j.dld.2023.08.061}
}
Kostenlos starten →